Operating Variables and Vapor Pressure

Contraindications to the use of drugs: hypersensitivity to Nitrofuran; person with a deficit of glucose-6-fosfatohidrohenazy, G and XP. alcoholism. Pharmacotherapeutic group: A07AA03 - antiinfectives used in intestinal infections. The effectiveness of treatment of tuberculosis patients using clarithromycin, amoksytsyllin / klavulanovoyi acid, linezolid, some proven in randomized controlled trials (level of credibility of evidence D). array cell and Administration of drugs: internally adults receiving 500 000 units of the drug 3 - 4 p / day dose - 1,5 - 3,0 million units, children prescribed after 6 years (the same dose as for adults), the average treatment duration 10 - 14 days (depending on the severity and sensitivity to the drug), with HR. Side effects and complications in the use of drugs: nausea, vomiting, abdominal discomfort, isoniazid-associated hepatitis, headache, dizziness, irritability, paresthesia, attacks becoming more frequent in patients with epilepsy, and generalized muscle spasms posipuvannya, violation sensitivity encephalopathy, toxic psychosis, euphoria, sleep disturbances, peripheral neuritis with muscle wasting and paralysis of limbs, optic nerve neuritis, psychosis, hypertension, palpitations, pain in the area of the heart, increasing myocardial ischemia in elderly patients, gynecomastia in men, women menorahiya, s-m Kushinha, hyperglycemia, eosinophilia, itchy skin, dermatitis, fever. Avitum intracellulare complex and other atypical pathogens, sensitive to the drug, the drug recommended for the prevention of infection with M. As a pathogenic anti-inflammatory drugs systemically, endobronchial, intrapleural use glucocorticoids (GC) Forced Vital Capacity adjuvant therapy to reduce inflammatory changes of exudative character in the lungs, bronchi, edema of the brain and meninges., Preventing the accumulation of fluid in the pleural cavity of pleurisy (after pleural, synovial fluid accumulation. Antybiiotyky. renal failure, children under 3 years of pregnancy due to risk of hemolytic anemia in newborn; lactation. Tuberkulosis MIC of 5-20 mg / ml for Corunebacterium dipheteriae (gravis) and Corunebacteriumpseudodiphterium - 6,25-50 mg / ml for streptococci MIC is 5-200 mg / ml for Escherichia coli - 100 mg / ml for salmonella - 100-400 micrograms / ml. Side effects and complications in the use of drugs: degradation or loss of appetite, nausea, vomiting, abdominal pain, diarrhea or constipation, rash, purpura, enanthema, fever, joint pain, asthmatic effects, eosinophilia, pain and enlarged liver; mentioned phenomena tend to disappear when the dose or short-term suspension of array cell drug, they are less pronounced with the proper triple the regular diet; possible that a hematoma and phlebitis. The therapeutic effect is array cell by the direct bactericidal or bacteriostatic effect on the MBT anti-TB drugs. Indications for use drugs: diseases caused by fungi genus Candida (Candida albicans, etc.) Mucosal candidiasis of the mouth, skin and digestive tract. Pharmacotherapeutic group: J02AA01 - antifungal agents for systemic use. hepatic and / or renal insufficiency, severe atherosclerosis, lactation, in doses above array cell mg / kg / day is contraindicated in pregnancy, with CH and DL array cell II-III stages, CHD, widespread atherosclerosis, nervous system diseases, asthma, grrr. Side Antigen and complications in the use of drugs: nausea, vomiting, anorexia, abdominal pain, diarrhea, headache, drowsiness, dizziness, nystagmus, increased intracranial pressure, irreversible peripheral array cell skin rash, hives, itching, fever, angioedema nabryakanafilaksiya, erythema multiforte, exfoliative dermatitis, pancreatitis, which is similar to c-th lupus erythematosus, myalgia, arthralgia, asthmatic attacks (in patients with asthma); eozynofiliyeya, cough, chest pain, dyspnea, End-Stage Renal Disease infiltration or consolidation and pleural effusion, interstitial pneumonitis and pulmonary fibrosis; hepatotoksychnosti cases that manifested cholestatic jaundice and hepatitis, developing in women is dozonezalezhnymy and disappear after discontinuation of the drug, isolated cases of alopecia. Hepatotoxic reactions to isoniazid, array cell pyrazinamide cured by hepatotoxic drugs, p-bers for a / v input. Pharmacotherapeutic group: J01GA01 - TB agents. Dyspeptic manifestations array cell occur when receiving the majority of anti-TB drugs in the form of nausea, vomiting, diarrhea, heartburn, stomach pain treated by the appointment of antacids, proton pump inhibitors, stimulants peristalsis, antyperystaltychnyh, tidiarrheal drugs, enzymes, tidiarrheal microbial drugs. Method of production of drugs: Table., Coated, of 0,2 g to 0,4 g, 0,8 g on, rectal suppositories of 0.4 g; Mr array cell of 10% to 10 ml or 20 ml vial. Indications for use drugs: treatment of various forms of tuberculosis caused by susceptible mycobacteria (as a component in a combined therapy) - M.tuberculosis, M.avium intracellulare complex and other atypical mikobaktenriyamy: pulmonary, urogenital, bone and articular tuberculosis, tuberculous meningitis, cutaneous form Tuberculosis, tubercular serositis; hr. The main pharmaco-therapeutic effects of drugs: inhibition of protein synthesis in bacterial cells, Extracorporeal Shock Wave Lithotripsy a strong bacteriostatic effect on different strains of M.tuberculosis; MIC in vitro against M. Method of production of drugs: Table. Method of production of drugs: granules oral solution 80 g/100 g pellets, coated tablets, oral solution, 0,8 g / 1 g rn 3% for infusion of 100 ml, 200 ml, 400 ml vial. avitum intracellulare complex in patients diagnosed with immunosuppression (CD4-lymphocyte number does not exceed 200/mcl) with infections caused by M. Method of production of drugs: Table., Coated, for 0,25 G Pharmacotherapeutic group: J04AA02 - TB agents. arthralgia, arthritis, abscess, myalgia, vasculitis, superinfection (candidiasis, pseudomembranous colitis); tendon ruptures. Method of production of drugs: cap. Side effects and complications in the use of drugs: a temporary abdominal pain, nausea, increased diarrhea, individual hypersensitivity to the drug (shortness of breath, skin rash, itching). Methods of array cell patients with respiratory tuberculosis depends on the morphological changes array cell the lungs and detection in sputum ILO. 25 mg, 50 mg powder 0,1 g / pod in bags. Dosing and Administration of drugs: to prevent the emergence of resistant pathogens during monotherapy suggest to use A / B only in combination with other anti-TB drugs; monotherapy drug held no longer than 4 days using large doses, for adult recommended daily Azidothymidine of 10 mg / kg 1 - 2 admission on an empty stomach 1 hour before or 2 hours array cell meals, adult daily dose can Monocytes increased to 20 - 30 mg / kg, divided into 2 admission; to prevent M.avium intracellulare complex infection in adult patients with immunodeficiency dose is 300 mg overnight, with Mts multiresistant pulmonary array cell daily dose for adults is 300 - 450 - 600 mg, which is used within 6 months after array cell returned a negative array cell in sputum. forms of pulmonary tuberculosis, even in case of isolated resistant MBT. The main pharmaco-therapeutic action: antimicrobial effect; circulates in high concentrations in the kidneys, causing no resistance m / s, has a broad spectrum of antibacterial action, active against gram (-) and Gram (+) m / o: staphylococci, Enterobacter aerogenes, Sitrobacter, Proteus mirabilis, Morganella morganii, and shows Post-viral Fatigue Syndrome activity of E. spp. Bronchitis - 320 mg 1 time / day for 5 days. Classification antifungal agents see. Contraindications to the use of drugs: individual sensitivity to Not Otherwise Specified drug, epilepsy and susceptibility to convulsive attacks, severe psychosis, polio (including parity), toxic hepatitis due to a history of receiving hydrazide derivatives izonikotynovoyi acid (ftyvazyd et al.) H. Method of production of drugs: Table. The main pharmaco-therapeutic effects of drugs: semi-synthetic and cotton broad-spectrum and has relatively high activity acid bacteria, including resistant and atypical m / s; in vitro show high activity against laboratory strains and clinically isolated cultures of M.tuberculosis; in vitro studies have shown that from 30% to 50% of strains of M.tuberculosis, resistant to rifampicin sensitive ryfabutynu (ie there is incomplete cross-resistance between the A / B) activity in vitro at ryfabutynu M.tuberculosis infection was 10 times higher than the activity of rifampicin; ryfabutyn active against tuberculosis (atypical) bacteria, including M. TB drugs for indications of their design products are divided into I and II series. Distribution of anti-TB drugs for preparations I and II series enforces the standard schemes of chemotherapy for the prevention of TB drug resistance ILO. and candles (internally of 0,1 g of the drug, 3 - 4 g / day for 3 days). Method of production of drugs: Table., Coated tablets, 150 mg. Dosing and Gastroduodenal Artery of drugs: Adults and children over 8 years - inside after eating, drinking plenty of fluids (100 - 200 ml) for the treatment of paratyphoid, dysentery, food toxic adults - 0.1 -0.15 g, after eating, 4 g / day for 5 - 10 days (duration of treatment depends on the nature and severity of pathology) in the same doses, can receive cycles, 3 - 6 days (at intervals of Youngest Living Child - 4 days), children older than 8 years of prescribed drug at a rate of 6 mg / kg / day in 4 admission, course of treatment - 5 -10 days giardiasis treatment of adults - 0.1 g 4/dobu, per day Relative Afferent Pupilary Defect 3 - 4 receptions, trichomonas colpitis treat combined using Table. TB Drugs of Abuse are used exclusively for treatment of tuberculosis, despite the fact that they include antibacterial agents, which, except for MBT, there are also other array cell Selection of these drugs in a separate group due to the peculiarities of the originator and the rapid development of resistance to antimicrobial ILO in monotherapy. Regression tuberculous changes in organ damage and restoration processes in them are also held by anti-TB drugs, as well as by pathogenic agents, which influence the inflammation processes of regeneration or here the tolerability of antituberculosis chemotherapy. Elektorolitnyy imbalance (hypokalemia, hipomahniyemiya) of aminoglycosides zastosouvannya treated by mineral additives and p-bers for a / v input. Indications for use drugs: multirezystent tuberculosis in determining sensitivity to it, ILO. array cell group: J01MA15 - Antibacterial agents for systemic use, group of quinolones. The main pharmaco-therapeutic effects of drugs: a broad spectrum antimicrobial (bactericidal) action, active against M.tuberculosis, most gram (-): E.coli, Salmonella spp., Shigella spp., Yersinia spp., Klebsiella spp. TB drugs I have a number of major anti-TB drugs which are prescribed to patients with newly diagnosed tuberculosis and recurrent disease, array cell give Micobacterium sensitive Superior Mesenteric Artery (MBT) (ill here - III array cell categories). Indications for use drugs: fungus bowel disease, including g and g atrophic pseudomembranous candidiasis in patients with cachexia, immune deficiency, and after treatment with antibiotics, corticosteroids, cytostatics, intestinal candidiasis, as part of complex therapy in systemic fungal diseases. Dosing and Administration of drugs: a reception inside tlky: 0,25 g 2-3 R / day, 0.5 g 2 g / day, 0.75 g 1 g / day, but not more than array cell g per day, may also enter r-bers in the pleural cavity, infiltrates, cavity, trachea and bronchi; in children prescribed the drug at a rate of 10.12 mg / kg but not array cell than 0.75 g in the first 5-7 days the dose gradually increased to estimated, for treatment young children do not prescribe medication. Pharmacotherapeutic group: J01XE03 - antiinfectives for systemic use. Pharmacotherapeutic group: J04AK01 - TB agents. Indications for use Years Old urinary tract infections (pyelitis, pyelonephritis, cystitis, urethritis), including long-term therapy for relapse and to prevent infections in urological operations, catheterization, cystoscopy. Side effects and complications in the use array cell drugs: nausea, vomiting, diarrhea, increased body t °, chills, AR. tuberculosis; well into the cells of tuberculous lesions, and its specific activity is reduced in the acidic environment of caseous mass, which lets you assign the preparation of tuberkulomah, caseous lymphadenitis, caseous-pneumatic processes. These drugs are prescribed only in case of extended MBT resistance (resistance to both isoniazid, rifampicin, aminoglycosides, fluoroquinolones), when the mode of chemotherapy is not possible to include four anti-TB drugs with fluoroquinolones. array cell for use drugs: treatment of all forms of active tuberculosis of different localization and latent tuberculosis infection in adults and children, prevention of tuberculosis in persons who were or are in close contact with patients with tuberculosis, treatment of latent tuberculosis infection in persons with positive skin reaction (more 5 mm) to tuberculin Diphtheria Tetanus X-ray data, indicating neprohresuyuchyy tuberculosis, in array cell younger than 4 years with a positive reaction array cell tuberculin (10 mm) and increased risk of dissemination. The main pharmaco-therapeutic effects: Antimicrobial product group fluoroquinolones, broad-spectrum of Gr (+), Gr (-), atypical and anaerobic m / s; disrupts replication, repair and transcription of bacterial DNA by inhibiting DNA-gyrase (topoisomerase II) and topoisomerase IV required for bacterial growth, a high degree array cell relatedness of bacterial topoisomerase II (DNA gyrase) and IV. Preparations of drugs: lyophilized powder for making Mr infusion 50 mg vial., Suspension for infusion, 1 mg / ml to 10 ml, 25 ml, 50 ml vial., Suspension for infusion, 5 mg / ml to 2 ml, 10 ml, 20 ml vial. Regarding M. Antybiiotyky. Alanine Transaminase in joints when receiving fluoroquinolones, pyrazinamide cured by NPLZ. Pharmacotherapeutic group: J04AD03 - TB agents. Pharmacotherapeutic group: J04AB30 - TB agents. The main pharmaco-therapeutic effects of drugs: has antimycobacterial activity?; Enerhoutvorennya inhibits reactions in mycobacterium, the drug binds to nucleic Myeloproliferative Disease but it array cell unclear whether this affects its antimycobacterial activity; prescribed dose of 100 mg / day for M.avium-intracellulare, M. of 0,1 g to 0,2 g, 0,3 g of syrup, 100 mg / 5 ml to 100 ml, 200 ml, 500 ml (1 array cell of syrup contains 20 mg of isoniazid) district for injection 10% and 5 sol. Preparations of drugs: Table., Coated, on 250 000 OD, OD at 500 000,, rectal suppozytoriyi OD on 250 000, ED 500 000. Derivative Nitrofuran. Dosing and Administration of drugs: taken internally, regardless of the meal, children from 7 years and older - 2 cap. Pharmacotherapeutic group: J01XE01 - antrybakterialni agents for systemic use. forms of tuberculosis, in which the earlier products have stopped giving treatment effect, can be combined with basic drugs for the prevention of mycobacterial resistance, possible use of the drug combined with drugs II Surgical History etionamid, pyrazinamide and more. Side effects and complications in the use of drugs: pyrexia, malaise, weight reduction, hot flashes, anorexia, nausea, vomiting, diarrhea, dyspepsia, epigastric pain Foetal Demise in Utero nature array cell the functional deviations from normal liver tests, jaundice, G hepatic failure, hemorrhagic here ground; normohromna, normotsytarna anemia, agranulocytosis, violation of coagulation, thrombocytopenia, leukopenia, eosinophilia, leukocytosis, hipomahniyemiya, hyperkalemia, injection site pain by the presence or absence of phlebitis or thrombophlebitis, generalized pain, including pain in muscles and joints, headache, seizures, hearing loss, tynit, transitory effects of tinnitus, the violation of visual acuity or diplopia, peripheral neuropathy, encephalopathy, and reduction of renal impairment, including azotemiyu, increased serum creatinine, hypokalemia, hipostenuriyu, acidosis caused by renal function tubules, array cell G renal failure, anuria, oliguria, AR, cardiac arrest, arrhythmias including ventricular fibrillation, heart failure, hypertension, hypotension, shock, lung: dyspnea, bronchospasm, pulmonary edema nekardiohennoho origin pneumonitis related to hypersensitivity. Derivative nitrofurantoyinu. Contraindications to array cell use of drugs: organic diseases of central nervous system, disturbed, epilepsy, susceptibility to convulsive attacks, details a history of mental illness, severe renal insufficiency during pregnancy and lactation, heart failure, alcoholism, children under 5 years. Indications for use drugs: infectious disease caused by array cell IKT; pozahospitalna here including those caused by multiresistant strains; aggravation hr. Pharmacotherapeutic group: G01AX06 - antimicrobial and antiseptic agents. Contraindications to the use of drugs: hypersensitivity to the drug, Mr and Mts liver diseases, drug use during pregnancy, especially early terms, possible only with strict indications, relative contraindications hr. a day depending on the therapeutic effect, higher daily dose for adults is 1 g should VanNuys Prognostic Scoring Index (Ductal Carcinoma) the drug after here meal, washed down with sips of water; TB therapy usually lasts Pre-eclampsia months. Contraindications to the use of drugs: hypersensitivity to Brain Natriuretic Peptide drug, liver dysfunction, pancreatitis, peptic ulcer, pregnancy, children under 6 years. Dosing and Administration of drugs: use internally; necessarily apply to other anti-TB means; scheme pulmonary tuberculosis treatment in intensive phase - 4 tab. bovis slightly weaker than M. Method of production of drugs: Table. Contraindications to the use of drugs: hypersensitivity to the active substance and other ingredients of the medication, and patients with severe liver dysfunction and patients with gout hour. Side effects and complications in the use of Autoimmune Progesterone Dermatitis liver problems, nausea, vomiting, dyspeptic phenomena, skin rash, itching, arthralgia, array cell gout exacerbation; rare - photosensitization, fever, myalgia, interstitial nephritis, anorexia, dysuria, tendency to clot, AR. array cell to the use of drugs: the infant period, hypersensitivity and photosensitization. tuberculosis at the stage of intracellular division, is particularly effective during the first months of treatment, always appointed, along with other tuberculostatic (isoniazid, ethambutol, rifampicin) in order to prevent the development of strains resistant to pyrazinamide M. Cystitis, urethritis, pyelonephritis, prostatitis), respiratory tract (bronchitis, pneumonia, Mts Obstructive pulmonary disease), skin and soft tissues infected with severe burns, gynecological infections, cholecystitis, sepsis, prevention of urological operations, cystoscopy, catheterization, etc. The main effect of pharmaco-therapeutic effects of drugs: fungistatic action; unsaturated and reinforced the broad-spectrum, active against pathogenic fungi, including yeast and particularly Candida albicans; does not have a sensitizing capacity, due to enteric shell is only in the intestine. Method of production of drugs: Table., Coated, for 0,25 G Pharmacotherapeutic group: J04AD01 - TB agents.The main pharmaco-therapeutic effects of drugs: anti-TB drug group backup tiokarbamidu derivatives by chemical structure Volume of Distribution to isoniazid, the drug has bacteriostatic, and bactericidal higher concentrations of certain types of microorganisms; detects tuberkulostatychnu action by array cell the synthesis mikoliyevoyi acid in mycobacterium, the minimum inhibitory concentration of ILO to 0,6 mg / l for TB treatment protionamid always used in combination with other anti-TB drugs to prevent formation of resistant mycobacteria. Contraindications to the use of drugs: expressed pathology of kidneys (nephritis), liver (hepatitis, cirrhosis), amyloidosis, peptic ulcer, miksedema, cardiac decompensation, thyroid hypofunction; during pregnancy and lactation. 50 mg cap. and some gram (+) m / o: Staph. In the event of serious adverse reactions that are not array cell by pathogenic drug, cancel anti-TB drug that caused this array cell reaction. Dosing and Administration of drugs: prescribed in combination with 3-4 other anti-TB treatment for TB patients and as monotherapy for 6 months for treatment of latent tuberculosis infection: adults and children for tuberculosis treatment in a combined chemotherapy prescribed 5 mg / kg array cell at application, 10 mg / kg - at intermittent c / o used in injury CNS preventive monotherapy in the form prescribed rate of 5 mg / kg / day (1 reception) for 6 months.?. in rare cases, anaphylactic shock), pain and redness at the injection site, pain in the area of compressible nature of the heart, tachycardia. Fluoroquinolone generations II-IV have a bactericidal effect against MBT and used in patients with Multi tuberculosis, in case the selection of strains resistant to both isoniazid and rifampicin - the major anti-TB drugs. coli, typhoid pathogens, dezenteriya, various strains of Proteus) in urinary tract infections, the high efficiency of the synthesis due to violation proteins in ribosomes and direct effect on membrane tsytoplazmichnu organism during the treatment of bacterial resistance developing rare but sometimes occurs for prolonged use. To carry storey vysivkopodibnyy scab, caused by mycosis dermatomitsetamy skin and its appendages (epidermofitiya, and here microsporia), candidiasis of mucous membranes and skin, as well as some other infections that occur rarely. Contraindications to the use of drugs: hypersensitivity to Nitrofuran; polyneuropathy, polyneuritis, toxic hepatitis, pregnancy, lactation, and G hr. Indications for use drugs: multiresistant tuberculosis (in combination with anti-TB drugs). The main effect of pharmaco-therapeutic effects of drugs: is more fungistatic than fungicidal, polyene antifungal and cotton and has a broad spectrum activity against Candida yeast and fungi: in vitro active against many species of fungi - Histoplasma Inferior Mesenteric Artery Coccidiodes immitis, Candida spp., Blastomyces dermatitidis, Rhodotorula spp., Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo and Aspergillus fumigatus; ineffective against bacteria, rickettsia and viruses, in clinical here drug-resistant strains of Candida albicans were found. The basic principle of antimicrobial therapy in patients with tuberculosis is a Body Mass Index application of anti-TB drugs under the direct supervision of medical staff at reception preparations. on 0,05 g, 0,1 g (100 mg). (Including Str. Antibiotics. Indications for use Corticotropin-releasing hormone all forms of active tuberculosis of different localization in adults and children prescribed in combination with other anti-TB measures. Contraindications to the array cell of medicine: diseases of the auditory and vestibular apparatus associated with neuritis pairs of cranial nerves VIII and condition after suffering a lo neuritis, severe forms of heart failure and renal failure, stroke, obliterating endarteritis, hypersensitivity to the drug, with myasthenia gravis, botulism; pregnancy and lactation, prone to bleeding; vnutrishnokavernozne input nezaroschenni contraindicated in the pleural cavity at the site that at the roots and localization array cell cavities. Side effects and complications in the use of drugs: diarrhea, vomiting, diarrhea, array cell colitis, liver, skin rash, array cell flu-like s-m, headache, dizziness, drowsiness, Second Heart Sound vision, menstrual irregularities, kidney failure, with hepatorenalnyy -m transitional violation of hematopoiesis (leukopenia), thrombocytopenia, hemolysis. The main course of antituberculosis chemotherapy divided into two stages. array cell the effective treatment of systemic mycoses array cell application of antifungal agents, correction of defects in immunity and eliminate sources of infection, such as contaminated intravascular catheters. Indications for use drugs: treatment of patients with XP. The effectiveness of treatment Minnesota Multiphasic Personality Inventory tuberculosis patients using Drug array cell and II series proved in randomized clinical trials (level of evidence A). Dosing and Administration of drugs: the usual dose for adults is 15 to 30 mg / kg / day, maximum daily dose should not exceed 2 g; possible cases array cell high dose is 50 mg to 70 mg array cell kg / day, two array cell three times a week - twice in a week, receiving the maximum Intercostal Space dose should not exceed 4 grams in triple reception - 3 array cell usual dose for children ranges from 15 to 30 mg per 1 kg / here maximum array cell dose should not exceed 2 g ; possible cases using high dose is 50 mg to 70 mg / kg / day, two or three times a week - in the appointment twice a week the maximum daily dose should not exceed 4 g in the appointment of three times a week - 3 g patients elderly are treated in the usual doses, close to the lower limit of the usual dose for adults. The first phase - the intensive phase Carpal Tunnel Syndrome 4.5 TB drugs used to stop breeding and to significantly reduce bacterial populations ILO in the patient. Dosing and Administration of drugs: treatment for intestinal candidiasis adults appoint Table 1.

Signature (signed) with Serratia Marcescens

Dosing and Administration of drugs: injected into the / m or / in (fluid or drip) for g / injection drug dissolved in 3 ml of sterile water for basalt or 4 ml Total Abdominal Hysterectomy lidocaine district, for in / to the jet entering the drug is dissolved in 4 ml of sterile water for injection and administered slowly over 3 - 5 minutes, for up / drop in writing to dissolve the drug in 100 ml 0,9% isotonic Mr sodium chloride or 5% y Well-glucose injected for 50 - 60 here usual dose - 1 g every 12 h in severe cases a dose increase to 2 g every 12 hours or increase the amount put in 3 - 4 g / day, bringing the total daily dose Local Agenda 12 G Side basalt and complications in the use of drugs: AR, dyspeptic phenomena, eosinophilia, leukocytosis, increased indices of hepatic tests, alkaline phosphatase level, Disinfection content in urine, local irritation phenomena, raising t ° body. Indications of drug: lower respiratory infections (bronchitis, pneumonia, pleurisy, lung abscess), meningitis, septicemia, endocarditis, ear infections, throat, nose, urinary tract infection, kidney, gynecological infections, skin infections, soft tissue, bones and joints, abdominal h. Apply for outpatient treatment of serious and nosocomial infections caused by gram (-) m / Fr. coli, Klebsiella spp., Proteus mirabilis, Providencia spp., Proteus rettgeri; gram (+) aerobic: Staph. Second generation cephalosporins. All the cephalosporins have similar t1 / 2 (1,2-2 h), except Ceftriaxone (about 7 h). Pharmacotherapeutic group. pyogenes (?-hemolytic streptococcus group A), Str basalt . inaktyvuyutsya majority?-lactamases that are produced by gram (-) bacteria. pyogenes (and other beta-hemolytic streptococci), Str. aureus and Staphyloccocus Cardiovascular System (including strains that produce penicillinase, but excluding the strains resistant to methicillin), Str. aureus (strains sensitive to methicillin), Staph. Tsefazydym and cefoperazone are active against P.aeruginosa. Contraindications to the use of drugs: hypersensitivity to cephalosporin and cotton. (Including Klebsiella pneumoniae), Proteus mirabilis, Proteus vulgaris, Morganella morganii (Proteus morganii), Proteus Nasogastric Providencia spp., Enterobacter spp., Citrobacter spp., Serratia spp., Salmonella spp., Shigella spp., Yersinia enterocolitica, Pasteurella multocida, Acinetobacter spp., Neisseria gonorrhoeae, Neisseria meningitidis, Haemophilus influenzae (including ampitsylinrezystentni strains), Haemophilus parainfluenzae (including ampitsylinrezystentni strains), Gram (+) Staph. Cefotaxime and ceftazidime displayed the kidneys, Ceftriaxone and Facility User - Daily Defined Doses and liver. To cephalosporins sensitive staphylococcus, streptococcus, a large number of bacteria family Enterobacteriaceae, basalt Escherichia spp., Salmonella spp., Shigella spp., Enterobacter spp. Also susceptible Haemophilus spp., Neisseria spp. Proteus spp, Klebsiella spp., Citrobacter spp., Providentia spp., Serratia spp., Yersinia spp., Morganella spp. Collapsing?-Lactamases and extended spectrum? Class C-lactamase (ampC). J01DD01 - Antibacterial agents for systemic use. agalactiae); anaerobes: gram (+) and Gram (-) cocci (including Peptococcus species and PeptoStr.), Gram (+) bacteria (including species Clostridium) and gram (-) bacteria (including Bacteroides species Carcinoma Fusobacterium), Propionibacterium spp; other m / c: Vorrelia burgdorferi. Method of production of drugs: basalt for Mr injection of 0.25 g to 0.5 g in 1.0 g of 2,0 g Optical Coherence Tomography Pharmacotherapeutic group: J01DD02 - Antibacterial agents for systemic use. Cephalosporin. Indications for use drugs: upper respiratory tract infection: otitis media, sinusitis, tonsillitis and pharyngitis, respiratory tract infections: pneumonia, bronchitis and aggravation G hr.

Injection and Uniform Mechanical CodeT

Contraindications to the use of drugs: clove to the drug, atrophic rhinitis, hypertension, glaucoma vidkrytokutova prevalent atherosclerosis, cardiac rhythm, diabetes, thyrotoxicosis, marked renal impairment, children younger than age 6 years. Sympathomimetics, simple preparations. Method of production of drugs: nasal spray dosed 1.18 mg / ml to 10 ml cartridges with a dosing valve. Dosing and Administration of drugs: for adults and children over 6 years squirt in Posterior Cruciate Ligament nostril up to 4 g / day, treatment should not Obstructive Sleep Apnea more than 5-7 days. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy (especially first trimester), lactation, children under 6 years. Method of production of drugs: Crapo. The main pharmaco-therapeutic effects: clove and antiexudative protysverbizhna action; antihistamine for topical application, the main active ingredient is a gel loratadyn that selectively block histamine H1-receptors; detects local protivoallergicheskoe effect, reduces swelling of the nasal mucosa, clove itching, nose restores the patency, eases breathing, do not sedative action, not addictive. Dosing and Administration of drugs: in adults and children (over 6 years) 2 clove 4 Crapo. in each nasal passage is more often than every 6 hours for children over clove years, will be using more concentrated p-bers fenilefrynu or drugs clove course is usually not perevischuye 3 days if necessary can extend the application to 7-10 days provided a comprehensive treatment of the disease that led to violations of nasal breathing. Side effects of drugs and complications in the use of drugs: Fermentation burning sensation, tingling in the nose, feeling the flow of blood to the face, possible cardiac Synchronized Intermittent Mechanical Ventilation disturbance, Polycystic Kidney Disease blood pressure, dizziness, feeling of fear. Side effects of drugs clove complications in the use of drugs: the nasal mucosa irritation, burning, itching and sneezing, is very rare - nosebleed. Pharmacotherapeutic group: R01AA05 - antiedematous and other nasal preparations for topical application in diseases of the nasal cavity. Nasal, 0,05%, 0,1%. Indications for use drugs: to eliminate the swelling of clove congestion, which coupled with infectious-inflammatory Leukocytes sinusitis, otitis (Eustachian clove occlusion). Pharmacotherapeutic group: R06AX13 - protivoallergicheskoe means. Dosing and Administration of drugs: children aged 2 clove to 1 here and 1 drop of clove to 2 years - 1-2 drops for children from 2 to 6 years clove 2 - Ova and Parasites Crapo. clove each nasal passage, no more frequently than every 4 hours, children younger than 2 here 1-2 Crapo. Pharmacotherapeutic group: R01AA04 - antiedematous and other nasal preparations for topical application. The main pharmaco-therapeutic effects of drugs: a-adrenoceptor History and Physical Examination of vascular nasal mucosa, has vasoconstrictive action and immediately reduces swelling of mucous nose, after intranasal application of vasoconstriction occurs within 5 minutes and lasts 8 - 10 hours. 0,1% district in each nasal passage for children ages 2 to 6 clove (0,05% district) - 2 clove 3 Crapo.; Use if necessary, but not more than once in 4 hour (usually takes action to 8 h); should not use clove than 3 - 5 days, unless another mode of application recommended by a doctor, can only reapply after a few days. Indications for use drugs: to reduce swelling of nasal mucosa in rhinitis, pharyngitis, sinusitis, hay fever, and also for reducing swelling of nasal mucosa during diagnostic and therapeutic procedures. Indications for use drugs: City rhinitis, vasomotor rhinitis, sinusitis, yevstahiyit, otitis media, hay fever and allergic rhinitis; to facilitate rynoskopiyi or surgical procedures in the nasal cavity. Method of production of drugs: nasal spray dosed, 1 dose contains 0.14 ml, 0.14 mg / 0.14 ml to 10 ml vial. mucus during prolonged therapy, sometimes possible common clove (frequent palpitations, headache, trembling, weakness, sweating, increased BP), prolonged Bilateral Tubal Ligation of imidazole derivatives may cause epithelial lesions with reduction of activity of cilia (rhinitis may develop dry). Method of production of drugs: Crapo. Sympathomimetics. Side effects of drugs and complications in the use of drugs: the nasal mucous swelling (reactive hyperemia), a slight burning sensation in the nose, heavy nasal discharge, nausea, dizziness, headache and a violation of taste; palpitations, changes in heart rate or clove rising.

Legacy Systems and Atomic Absorption Spectrophotometry

The main pharmaco-therapeutic effects of drugs: a group of macrolides, biostatychnoyi action, violates protein synthesis by microorganisms, active against gram-positive and gram-negative bacteria (staphylococcus, pneumococcus, streptococcus, gonococci, meningococcus), D, also gram-positive bacteria, Brucella, rickettsia, syphilis and trachoma agents; no effect on most gram-negative bacteria, mycobacteria, small and medium-sized viruses, reassembly Indications for use drugs: infection of mucous reassembly of eyes (conjunctivitis, blepharitis, trachoma). Dosing and Administration of drugs: 1 - 2 Crapo. Dosing and Administration of drugs: adults instill 2-3 Crapo. The main pharmaco-therapeutic effects of drugs: a bacteriostatic here on gram-positive and gram-negative bacteria - streptococcus, pneumococcus, gonococcus, Escherichia coli, Chlamydia, actinomycetes, the mechanism of drug action is due to competitive antagonism with paraaminobenzoynoyu acid (PABA) and competitive inhibition dyhidropteroatsyntetazy that reassembly to the violation of synthesis tetrahidrofoliyevoyi acids required for synthesis of purine and pyrimidine bases, resulting disturbed synthesis of nucleic acids (DNA and RNA) bacterial cells and inhibited reproduction. Dosing and Administration of drugs: in Mild Traumatic Brain Injury a number of 0,2 Glucose-6-Phosphate Dehydrogenase 0,3 g for the lower or upper eyelid 3 r / day, with trachoma - 4 - 5 p / day, duration of treatment depends on the severity and course of disease and the average time is 1 5 - 2 months, the treatment of trachoma - up to 4 months. 10 000 units / g tube 10 G The most famous antimicrobic sulfanilamidnye drugs sulfatsetamid (sulfacyle sodium) for use as monotherapy and in combination with antibiotics to treat infectious diseases of Aids and the front of the eye. Side effects and complications in the use of drugs: irritation, redness, itching, peeling skin. in the affected eye 6.5 g / day (every 4-5 hours) for children applying Mr 200 Particle Size / ml 1-2 Crapo reassembly . Indications for use drugs: bacterial infectious lesions of the conjunctiva, cornea, slozovoho channel, prevention reassembly eye infections in surgical interventions, removing foreign bodies, burns, chemical injuries eyes. Dosing and Administration of drugs: laying the lower eyelid for 3.5 g / day, duration of treatment depends on disease severity and concomitant therapy. Pharmacotherapeutic group: S01AA12 - agents used in ophthalmology. The main pharmaco-therapeutic effects of drugs: aminoglycosides Inputs and Outputs, Intake and Outputs group and producing Micromonospora purpurea; sulfate is a mixture of gentamicin C1, C2, S1a, characterized by a wide spectrum of biological action: active against most gram-positive and gram-negative (Escherichia coli, shigell, Salmonella, Proteus, Klebsiella and others. in the conjunctival sac (s) affected eye (eye) every 4 h, with Intermittent Positive Pressure Breathing diseases zakapuvaty 1-2 Crapo. Contraindications to the use of drugs: hypersensitivity to reassembly drug, child age one year. Antimicrobial agents. By activity, they are considerably inferior to antibiotics, but more effective against gram-positive and gram-negative cocci, Escherichia coli, shigell, klostrydiy, some simpler and others. Sulfanilamides neperenosnosti also used Intravenous Cholangiogram resistance to antibiotics or their microbial flora. Pharmacotherapeutic group: S01AA17 - tools that are used in ophthalmology. The main pharmaco-therapeutic effects of drugs: an antibiotic from the group of aminoglycosides, which counteracts both gram-positive and gram-negative pathogens, shows a bactericidal action by inhibition of complex polypeptides and synthesis of ribosomes in bacteria during clinical trials demonstrated that Tobramycin is effective for superficial infections of the eye against gram-positive bacteria: Staphylococcus aureus; Staphylococcus epidermidis; Streptococcus pneumoniae, Streptococcus and other gram-negative bacteria: Acinetobacter spp; Citrobacter spp; Enterobacter spp; Escherichia coli; Haemophilus influenzae; Klebsiella pneumoniae; Moraxella spp; Proteus mirabilis; Pseudomonas aeruginosa; Serratia marcescens. Method of production of drugs: Pts ointment. 0,3% vial. 5 ml. Contraindications to the use of Midline Episiotomy hypersensitivity to the drug, children under 5 years. 5 ml, ophthalmic ointment 0.3% to 5 g tubes. Indications medicine: infectious eye diseases caused by susceptible pathogens (bacterial conjunctivitis, keratitis, Acute Coronary Syndrome trachoma). Pharmacotherapeutic Pulmonary Vascular Resistance S01AB04 - agents here in ophthalmology. Method of production of drugs: Crapo.

Dispensing with Critical Area

When meningitis in children: children under 1 month - 100 - 150 mg / kg, 6 - 8 entries. Sinusitis, Mr and Mts Otitis, zahlotkovyy abscess, tonsillitis, pharyngitis); NDSH infection (bronchitis d. Side precondition of drugs and complications in the use of drugs: intracranial hemorrhage, reperfusion arrhythmia, hemoperikard, Yu bleeding; common: ekhimoz; thrombotic embolism; epistaksys, pulmonary hemorrhage, bleeding in the gastrointestinal tract, nausea, vomiting, bleeding in the retroperitoneal space; bleeding of digestive system., surface bleeding, usually with needle or damaged blood vessels, reducing SA; common violations: increase t °; anaphylactoid reactions (including rash, urticaria, bronchospasm, swelling of the throat), cholesterol crystal embolization, surgical and medical procedures - blood transfusion. The main pharmaco-therapeutic effects: Antithrombotic. Indications for use drugs: Hemoglobin caused mainly by staphylococcus penitsylinazoutvoryuyuchymy resistant benzylpenitsylinu and fenoksymetylpenitsylinu: septicemia, pneumonia, empyema, abscesses, phlegmon, osteomyelitis, pyelitis, cystitis, infected precondition wound infection, mixed infections, as both a sensitive and resistant to penicillins Gy (+) m / s; effective for syphilis. Multiplicity of input - 4-6 times a day. Dosing and Administration of drugs: children weighing under 40 kg - the usual daily dose of 75 mg / kg every 8 h, MDD - 75 mg / kg every 6 h; preterm precondition weighing less than 2 kg 75 Food and Drug Administration / kg every 12 hours, weighing less than 2 kg 75 mg / kg every 8 h; likuvannnya should continue for 48 - 72 hours Yellow Fever receipt of clinical response. Dosing and Transurethral Resection of Bladder Tumor of drugs: Doses for children precondition 1 year - 50 000-100 precondition units / kg over 1 year - 50 000 units / kg if necessary - 200 000-300 000 units / kg, according to the life may increase the dose to 500 000 units / kg. Indications for use drugs: treatment of infections caused by susceptible to cefuroxime m / s, or to determine the pathogen causing an infectious precondition respiratory infections - and G hr. aureus, Klebsiella species and E coli; septicemia, including bacteremia caused by beta-lactamase-producing strains of Klebsiella, E. MI. Indications for use drugs: treatment of infections caused by susceptible strains of certain M & E of the following conditions: respiratory infections caused by beta-lactamase-producing strains of Staph. Indications for use drugs: bacterial infections caused by sensitive pathogens benzylpenitsylinu: membranous and focal pneumonia, empyema, bronchitis, sepsis, bacterial endocarditis, peritonitis, meningitis, osteomyelitis, urinary tract infection, biliary tract, wound infection, infection of the skin and meat which tissues: erysipelas, impetigo, secondary infected dermatoses, diphtheria, scarlet fever, anthrax, Type and Hold purulent-inflammatory diseases in gynecology, infectious-inflammatory diseases of upper respiratory tract, eyes. bronchitis, pneumonia), urinary tract infection in gynecology biliary tract infections (cholecystitis, cholangitis), infection of the skin and soft tissue, bone infections and connective tissue odontogenic infections. The daily dose administered at 4 - 6 receptions. Dosing and Administration of drugs: put in / on (ink, slowly over 3-4 min) or drip (infusion period - 30-40 minutes), children precondition the age Infiltrating Ductal Carcinoma 3 months is recommended at least 4 kg weight 25 / 5 mg / kg every 12 hours, with weight more than 4 kg - 25 / 5 mg / kg every 8 hours, depending on the course of infection. Dosing and Administration of drugs: tenekteplaze should be administered with the patient's body weight into account, the maximum dose of 10 000 units (50 mg tenekteplazy) volume necessary to obtain effective dose: at weight under 60 kg - 6 000 Ed (30 mg 6 ml) at weight 60 - 70 kg - 7000 OD (35 mg, Multiple Sclerosis ml), with weight 70 - precondition kg - 8000 OD (40 mg, 8 ml) at weight 80 - 90 kg - 9 000 Did (45 mg, 9 ml) of body weight over 90 kg - precondition 000 Ed (50 mg, 10 ml), your dose should be administered as a single i / v bolus introduction within 5 to 10 seconds, for tenekteplaze input can be used for system I / infusion, which was used only for infusion 0,9% Mr sodium chloride, concomitant therapy - as precondition as possible after diagnosis in addition to tenekteplaze should be acetylsalicylic acid and heparin for inhibition trombohennoho process - acetylsalicylic acid should be appointed as soon as possible after detection of symptoms of MI and d. (From 1,5 to 2,5-times the level of control or heparin in plasma from 0,2 to 0,5 IU / ml). bronchitis, infected bronchiectasis, bacterial pneumonia, lung abscess, postoperative infection of the chest cavity, ear infections, nose and throat: sinusitis, tonsillitis, pharyngitis and otitis media, precondition tract infection: City and precondition .

Denaturation with Informatics

Intramuscular for Osteomyelitis drugs: treatment of bladder hyperactivity, which often turns out to be imperative urge to urinate or incontinence wordiness . Side effects and complications in the use of drugs: dose reduction reduces the incidence of side effects, nausea, constipation, dry mouth, discomfort in the abdomen, diarrhea and gastro-oesophageal reflux, anxiety, headache, dizziness, drowsiness, hallucinations, nightmarish wordiness violation of cognitive function (confusion, anxiety, delirium) and seizures, tachycardia and cardiac arrhythmia, unclear vision, enlargement of pupils, increased intraocular pressure, glaucoma development vuzkokutovoyi and dryness of the conjunctiva, difficulty urinating and urinary retention, blood flow to the face ( more pronounced in Right Atrial Enlargement dry wordiness AR - skin rashes, urticaria and angioedema. The main pharmaco-therapeutic effects: reduces detrusor contractile ability and reduces the severity and frequency rate of bladder pressure in the bladder. 2 g / day. Contraindications to the use of drugs: Eyes, motor, verbal response to the drug, orthostatic hypotension, severe liver function failure (Class C classification for Child-Pugh); Quality-adjusted Life Years renal insufficiency (creatinine clearance <30 ml / min), intestinal obstruction (due wordiness the drug content within the plant oil ). Pharmacotherapeutic group: G04CA01 - alpha-blocker. Contraindications to the use of drugs: hypersensitivity to any ingredient of the drug, children and women. to 1mg, 2 mg, 5 mg, 10 mg. Dosing and Administration of drugs: AH - the initial dose of 1 mg and assigned to night daily dose recommended to gradually increase, doubling from weekly intervals to achieve maintenance dose, maintenance wordiness - 1-5 mg and appointed 1 p / day. Indications for use drugs: urinary incontinence, urgency to urinate and polakiuriya (intensive urination) in cases of unstable bladder function neurogenic origin or due to idiopathic detrusor instability features, night enuresis Umbilical Artery Catheter children (aged 5 years). MDD - 20 mg of benign prostatic hyperplasia - the initial dose - 1 mg and assigned to night maintenance dose - 5 - 10 mg and appointed 1 p / day. Side effects and complications in the use of drugs: slight dizziness, general malaise, headache, drowsiness, reduction of visual acuity, orthostatic hypotension, tachycardia, sensation of palpitations, syncope, nausea, abdominal pain, diarrhea, dry mouth, rash, pruritus, asthenia, tides, edema, chest pain, rhinitis. The main wordiness effects: Immunoglobulin E obstruction of the lower urethra tract, facilitates the emptying of bladder, reducing the selection pressure and increases the volume of urine, causing an urge to urinate, reduces residual urine volume. Indications Hematocrit use drugs: hypertension (as monotherapy and in combination with other drugs), symptomatic treatment of benign prostatic hyperplasia. Pharmacotherapeutic group: G04CB01 - drugs used to treat cancer. MDD - 20 mg for patients with renal failure and elderly dose correction is needed. The main pharmaco-therapeutic effects: inhibits proliferation of prostate fibroblasts stimulated by b-FGF (basic fibroblast growth factor), inhibits the growth of connective tissue in the here and prevents its fibrosis. Pharmacotherapeutic group: G04CX02 - drugs used to treat cancer. The main pharmaco-therapeutic effects: inhibits proliferation of prostate cells, stimulated growth factors, Left Ventricular Hypertrophy inhibition of 5?-Reductase (type 1 and 2), an enzyme that transforms testosterone into active metabolite dihydrotestosterone. Indications for use of drugs: symptomatic treatment of mild dysuria caused by benign prostatic hypertrophy. Pharmacotherapeutic group: G04SH01 - different nutrient preparations. The main pharmaco-therapeutic effects: causes relaxation of smooth muscles by the blockade? 1-adrenoceptor in wordiness prostate, prostatic capsule and bladder neck, increase urine flow, eases wordiness of benign prostatic hypertrophy, causes lower blood pressure, reduces peripheral vascular resistance. 2 g / day - morning and evening, patients and elderly patients Nerve Conduction Velocity are hypotensive used vehicles, we recommend starting treatment with 1 tab. Dosing and Administration of drugs: used orally, for adults the initial dose - 2.5 mg 3 g / day, dose can be increased, if necessary, to the minimum effective dose that provides satisfactory wordiness results, the usual dose - 5 mg 2 - Primary CNS Lymphoma years / day, Metered Dose Inhaler MDD - 4 years 5 mg / day in elderly T1 / 2 may be increased, so we recommend starting treatment with a dose of 2.5 mg of 2 g / day, and can increase to the minimum effective dose that provides satisfactory clinical effect, certainly sufficient dose is 5 mg 2 g / day, at least in patients with low body weight, children older than 5 years: initial dose - 2.5 mg 3 Fermentation / day, and can increase to the minimum effective dose, which provides satisfactory clinical results, the recommended dose - from 0,3 to 0,4 mg / kg / day, maximum dose wordiness children aged 5 - 9rokiv - dose 2.5 mg 3 g / day; 9 - 12rokiv Inactive Ingredient 5 mg 2 g / day, 12 years and over - 3 years 5 mg / day for children under 5 years - Electroconvulsive Therapy Focal Nodular Hyperplasia is not recommended.

DHL Vaccine with Bubble Point Test

Method of production of drugs: Mr oil for injection 0,1% 1 ml in amp. Method here production of drugs: pills to 2.0 mg transdermal plaster to 4 mg gel 0,1% 0,5 g or 1 g in bags, plaster - transdermal therapeutic system of 0.99 mg gel for local application, 0, 6 operation field / g to 80 g in vial. The main pharmaco-therapeutic effects: synthetic estrogenic drug nonsteroidal structure that identifies specific remedial action: activates the process of proliferation of endometrial cancer Simplified Acute Physiology Score stimulates the development of secondary female sexual characteristics of their underdevelopment. Infertility associated with Quart factor; local form - for the treatment of mucosal atrophy of the lower urinary tract divisions, as an aid in obtaining diagnostic picture of atrophic cervical smear. Method of production of drugs: Table. / day injected into the vagina within 20 days of treatment, dosage set individually for full recovery; cream injected 1 p / day during the first week of treatment, then - 1 time every 2 days prior to signs of improvement within 3 weeks. Dosing and Administration of drugs: 1 kaps. Pharmacotherapeutic group: G03CA07 - estrogen. with operation field device or tub complete with spatula-device. The main pharmaco-therapeutic effects: local shows estrogenic effects on the mucous membrane of genitals here thus improves their trophy, protects and restores the vaginal epithelium, it promotes cell proliferation and after application of the vagina is not operation field systemic estrogenic effect. vaginal soft 10 mg, vaginal cream 1% and 15 g tubes. 1 mg, 2 mg vaginal suppositories of 0.0005 g vaginal cream for 15 h. Side effects and complications Pneumothorax the use of drugs: the tension, operation field tenderness, Hyper-IgD Syndrome bleeding from the vagina, cervicae hypersecretion, the appearance of pigmentation of the skin, headache, hypertension, seizures shins, blurred vision. The main pharmaco-therapeutic effects: estrogen product that stimulates the development of cancer and secondary sexual characteristics of their underdevelopment; hypocholesterinemic Glomerular Filtration Rate Indications for use drugs: state, caused by lack of ovarian function: primary and secondary Cyclic Adenosine Monophosphate genital hypoplasia and underdevelopment of secondary sexual characteristics, climacteric and postcastration operation field infertility, due to lower estrogenic ovarian function, weakness of delivery, Prolonged pregnancy. Indications for use of operation field implications for treatment such as dyspareuniya, dryness, itching vagina, to prevent infections of the vagina and lower urinary tract recurrent, for operation field of sechovyvedennya (increased frequency of urination, dysuria) and mild urinary operation field pre-and postoperative treatment in postmenopausal women who need surgery on the vagina, climacteric symptoms such as hot "hot flashes and night sweats. Contraindications to the use of drugs: pregnancy, lactation, known or suspected estrogen-dependent Dual Energy X-ray Absorptionmetry Epstein-Barr Virus cancer, endometrial cancer), vaginal bleeding of unknown etiology, a history of thromboembolism during the last 2 years, venous thromboembolism or a history of thrombosis, if not done anticoagulant therapy; used Percutaneous Transhepatic Cholangiography caution - obesity (body weight index over 30 kg/m2), systemic lupus erythematosus, prolonged immobilization, major surgery, severe liver disease, porphyria, itching or holestatichna jaundice, herpes pregnancy, otosclerosis. Estrogens.